StockData
Lyell Immunopharma, Inc. logo

Lyell Immunopharma, Inc. (LYEL) stock

LYELNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 6/30
$13.67−0.98 (-6.69%)

Close on Nov 17, 2026Market cap $334.98MP/E –Yield –

Lyell Immunopharma ebitda

EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.

Lyell Immunopharma's ebitda for the twelve months ending Jun 30, 2026 was -$246.98M. For fiscal 2025 it was -$257.87M. The highest annual figure on record is -$100.83M in fiscal 2019.

Annual ebitda

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$257.87M–
FY2024Dec 31, 2024-$339.12M–
FY2023Dec 31, 2023-$226.76M–
FY2022Dec 31, 2022-$169.04M–
FY2021Dec 31, 2021-$201.15M–
FY2020Dec 31, 2020-$207.64M–
FY2019Dec 31, 2019-$100.83M–

Quarterly ebitda

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$45.12M–
Q1 FY2026Mar 31, 2026-$41.93M–
Q4 FY2025Dec 31, 2025-$125.25M–
Q3 FY2025Sep 30, 2025-$34.69M–
Q2 FY2025Jun 30, 2025-$44.01M–
Q1 FY2025Mar 31, 2025-$53.93M–
Q4 FY2024Dec 31, 2024-$196.12M–
Q3 FY2024Sep 30, 2024-$45.83M–
Q2 FY2024Jun 30, 2024-$46.63M–
Q1 FY2024Mar 31, 2024-$50.55M–
Q4 FY2023Dec 31, 2023-$54.45M–
Q3 FY2023Sep 30, 2023-$53.94M–
Q2 FY2023Jun 30, 2023-$60.84M–
Q1 FY2023Mar 31, 2023-$57.53M–
Q4 FY2022Dec 31, 2022-$9.74M–
Q3 FY2022Sep 30, 2022-$61.82M–
Q2 FY2022Jun 30, 2022-$33.09M–
Q1 FY2022Mar 31, 2022-$64.39M–
Q4 FY2021Dec 31, 2021-$42.97M–
Q3 FY2021Sep 30, 2021-$45.07M–
Q2 FY2021Jun 30, 2021-$59.70M–
Q1 FY2021Mar 31, 2021-$53.41M–
Q4 FY2020Dec 31, 2020-$38.07M–
Q3 FY2020Sep 30, 2020-$35.74M–

More Lyell Immunopharma figures

See a number that looks wrong?